ES2163512T3 - Nuevo compuesto, procedimiento para producirlo, y agente antitumoral. - Google Patents

Nuevo compuesto, procedimiento para producirlo, y agente antitumoral.

Info

Publication number
ES2163512T3
ES2163512T3 ES95920265T ES95920265T ES2163512T3 ES 2163512 T3 ES2163512 T3 ES 2163512T3 ES 95920265 T ES95920265 T ES 95920265T ES 95920265 T ES95920265 T ES 95920265T ES 2163512 T3 ES2163512 T3 ES 2163512T3
Authority
ES
Spain
Prior art keywords
group
hydrogen atom
sub
low
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95920265T
Other languages
English (en)
Spanish (es)
Inventor
Kyoji Tomita
Katsumi Chiba
Shigeki Kashimoto
Koh-Ichiro Shibamori
Yasunori Tsuzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2163512T3 publication Critical patent/ES2163512T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES95920265T 1994-06-14 1995-06-06 Nuevo compuesto, procedimiento para producirlo, y agente antitumoral. Expired - Lifetime ES2163512T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13
PCT/JP1995/001110 WO1995034559A1 (en) 1994-06-14 1995-06-06 Novel compound, process for producing the same, and antitumor agent

Publications (1)

Publication Number Publication Date
ES2163512T3 true ES2163512T3 (es) 2002-02-01

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95920265T Expired - Lifetime ES2163512T3 (es) 1994-06-14 1995-06-06 Nuevo compuesto, procedimiento para producirlo, y agente antitumoral.

Country Status (26)

Country Link
US (1) US5817669A (cg-RX-API-DMAC7.html)
EP (1) EP0787726B1 (cg-RX-API-DMAC7.html)
JP (1) JP3391796B2 (cg-RX-API-DMAC7.html)
KR (1) KR100350921B1 (cg-RX-API-DMAC7.html)
CN (1) CN1053668C (cg-RX-API-DMAC7.html)
AT (1) ATE209645T1 (cg-RX-API-DMAC7.html)
AU (1) AU679859B2 (cg-RX-API-DMAC7.html)
BR (1) BR9508037A (cg-RX-API-DMAC7.html)
CA (1) CA2192824C (cg-RX-API-DMAC7.html)
CZ (1) CZ292631B6 (cg-RX-API-DMAC7.html)
DE (1) DE69524251T2 (cg-RX-API-DMAC7.html)
DK (1) DK0787726T3 (cg-RX-API-DMAC7.html)
ES (1) ES2163512T3 (cg-RX-API-DMAC7.html)
FI (1) FI112485B (cg-RX-API-DMAC7.html)
HU (1) HU220072B (cg-RX-API-DMAC7.html)
MX (1) MX9606331A (cg-RX-API-DMAC7.html)
NO (1) NO307255B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ287139A (cg-RX-API-DMAC7.html)
PL (1) PL181867B1 (cg-RX-API-DMAC7.html)
PT (1) PT787726E (cg-RX-API-DMAC7.html)
RO (1) RO117793B1 (cg-RX-API-DMAC7.html)
RU (1) RU2151770C1 (cg-RX-API-DMAC7.html)
SI (1) SI0787726T1 (cg-RX-API-DMAC7.html)
SK (1) SK281341B6 (cg-RX-API-DMAC7.html)
TW (1) TW319769B (cg-RX-API-DMAC7.html)
WO (1) WO1995034559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002136A (es) 2001-09-26 2005-03-07 Bayer Pharmaceuticals Corp Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados.
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
WO2004091627A2 (en) * 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
AU2004272414B2 (en) * 2003-09-10 2009-05-28 Kyorin Pharmaceutical Co., Ltd. 7-(4-substituted 3- cyclopropylaminomethyl-1- pyrrolidinyl) quinolonecarboxylic acid derivative
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
AU2005222607B2 (en) * 2004-03-15 2010-11-25 Sunesis Pharmaceuticals, Inc. SNS-595 and methods of using the same
RU2405781C2 (ru) * 2004-10-14 2010-12-10 Ф.Хоффманн-Ля Рош Аг 1, 5-нафтиридиназолидиноны, обладающие cdk1 антипролиферативной активностью
US7501428B2 (en) * 2004-10-14 2009-03-10 Hoffmann-La Roche Inc. Quinazoline thiazolinones
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
CA2619663A1 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
KR20080041298A (ko) * 2005-09-02 2008-05-09 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한(＋)-1,4-디히드로-7-[(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
KR20170118936A (ko) * 2005-09-02 2017-10-25 선에시스 파마슈티컬스 인코포레이티드 암 치료를 위한 (＋)-1,4-디히드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
CN101305000A (zh) * 2005-09-14 2008-11-12 詹森药业有限公司 作为c-fms激酶抑制剂的5-氧代-5,8-二氢-吡啶并-嘧啶类
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DK2049109T3 (en) * 2006-08-02 2016-01-11 Sunesis Pharmaceuticals Inc Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
MX2010004350A (es) * 2007-10-22 2010-05-19 Sunesis Pharmaceuticals Inc Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
AU2008335772B2 (en) 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
RU2558835C2 (ru) 2009-02-27 2015-08-10 Санесис Фармасьютикалз, Инк. Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
BR112013029201B1 (pt) 2011-05-13 2022-08-09 Array Biopharma Inc Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
AU2018238079B2 (en) * 2017-03-24 2022-03-03 Wakunaga Pharmaceutical Co., Ltd. Novel pyridone carboxylic acid derivative or salt thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
EP0154780B1 (en) * 1984-01-26 1990-04-11 Abbott Laboratories Quinoline antibacterial compounds
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
NZ216519A (en) * 1985-06-13 1989-02-24 Schering Corp Polycyclic compounds and pharmaceutical compositions
EP0226624A1 (en) * 1985-06-14 1987-07-01 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
HUT75777A (en) 1997-05-28
EP0787726A4 (cg-RX-API-DMAC7.html) 1997-08-06
SI0787726T1 (en) 2002-04-30
PL317726A1 (en) 1997-04-28
DE69524251T2 (de) 2002-07-11
SK157496A3 (en) 1997-08-06
KR100350921B1 (ko) 2002-11-18
HK1000495A1 (en) 2002-07-19
PL181867B1 (pl) 2001-09-28
CA2192824A1 (en) 1995-12-21
NO965305D0 (no) 1996-12-11
DE69524251D1 (de) 2002-01-10
CZ364396A3 (en) 1997-06-11
MX9606331A (es) 1997-03-29
CA2192824C (en) 2006-11-07
CN1053668C (zh) 2000-06-21
BR9508037A (pt) 1997-09-16
JP3391796B2 (ja) 2003-03-31
SK281341B6 (sk) 2001-02-12
NZ287139A (en) 1997-07-27
AU2576795A (en) 1996-01-05
HU220072B (hu) 2001-10-28
WO1995034559A1 (en) 1995-12-21
AU679859B2 (en) 1997-07-10
NO307255B1 (no) 2000-03-06
FI965020A7 (fi) 1996-12-16
DK0787726T3 (da) 2002-02-11
HU9603455D0 (en) 1997-02-28
ATE209645T1 (de) 2001-12-15
RO117793B1 (ro) 2002-07-30
CZ292631B6 (cs) 2003-11-12
EP0787726B1 (en) 2001-11-28
NO965305L (no) 1997-02-04
EP0787726A1 (en) 1997-08-06
TW319769B (cg-RX-API-DMAC7.html) 1997-11-11
FI965020A0 (fi) 1996-12-13
PT787726E (pt) 2002-04-29
US5817669A (en) 1998-10-06
CN1158614A (zh) 1997-09-03
FI112485B (fi) 2003-12-15
RU2151770C1 (ru) 2000-06-27

Similar Documents

Publication Publication Date Title
ES2163512T3 (es) Nuevo compuesto, procedimiento para producirlo, y agente antitumoral.
ATE186727T1 (de) Substituierte 3-arylidinene-7-azaoxindol verbindungen und verfahren zu ihrer herstellung
ES2139943T3 (es) Nuevos inhibidores de la sintasa de prostaglandina.
ES2124612T3 (es) Dihidrodibenzo(b,f)azepinas, substituidas, metodo para su preparacion, su utilizacion en el tratamiento de diversos trastornos del sistema nervioso central y composiciones farmaceuticas que las contienen.
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
AR002260A1 (es) Compuestos derivados de acido [4-(indazol-3-il)-piperidin-1-il]-acetico, procedimiento para su preparacion, composicion farmacuetica que los contienen,el uso de los mismos en la preparacion de un agente terapeutico, metodo de tratamiento y compuestos intermediarios.
MX9306529A (es) Derivados de pirazol condensado, metodo para fabricarlos y composicion farmaceutica que los contiene
ES543786A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo dietilaminoalcoxi sustituido y sus sales deadicion acidas y amonicas cuaternarias
ES2039485T3 (es) Un procedimiento para la preparacion de un compuesto 3,4-dihidropirimidina n-sustituido.
ES543802A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo n-carbamiloxi sustituido
ATE52776T1 (de) 1-phenyl-3-benzazepine.
ES544708A0 (es) Procedimiento para preparar dihidro-1,4-tiazinas aroil-sustituidas
PH15932A (en) Method for treating inflammation
SE8404720L (sv) Forfarande for framstellning av kondenserade as-triazinderivat
ES493044A0 (es) Un procedimiento para la preparacion de agentes antibacterianos beta-lactanicos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 787726

Country of ref document: ES